Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.
Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.
复制标题
DOI：
10.3390/genes13122325
复制
发表时间：
2022-12-10
期刊：
影响因子：
3.5
通讯作者：
Balaraman, Ashok Kumar
中科院分区：
文献类型：
--
作者：
Jayaraj, Rama;Polpaya, Karthikbinu;Kunale, Milind;Muthukaliannan, Gothandam Kodiveri;Shetty, Sameep;Baxi, Siddhartha;Mani, Ravishankar Ram;Paranjothy, Chitraabaanu;Purushothaman, Vinosh;Kayarohanam, Saminathan;Janakiraman, Ashok Kumar;Balaraman, Ashok Kumar
关键词：
背景：化疗耐药是抗击头颈部肿瘤的一个重要障碍，破解这种耐药可以拓宽此类化疗药物的治疗应用。这篇系统的综述和荟萃分析探讨了microRNA(MiRNA)表达对头颈癌(HNC)化疗耐药的影响。本研究的目的是评价microRNA表达对HNC患者化疗耐药的诊断作用，并探讨miRNAs作为生物标志物和寻找新的治疗靶点的作用。方法：我们进行了全面的书目搜索，包括Scope us、PubMed和Science Direct书目数据库。这些搜索符合一套预定义的搜索策略。根据PRISMA指南，在完成文献搜索后制定了纳入和排除标准。提取的数据项在MS Excel中制表和整理。该电子表格用于确定miRNA表达对HNC化疗耐药的诊断作用的效应大小估计、风险比(HR)和95%可信区间(95%CI)。采用随机效应模型进行综合荟萃分析。收集的数据之间的异质性使用Q检验、Tau2、I2和Z测量进行评估。采用Egger‘s偏倚指标检验、Orwin和经典故障安全N检验、Begg和Mazumdar等级收集检验以及Duval和Twedie’s Trim and Fill方法检验纳入研究的发表偏倚。结果：在整理了23项研究的数据后，在2189人中观察到34个miRNAs的调节异常。这些数据是从23项研究中收集的。在所考虑的34个miRNAs中，22个上调，12个下调。TaqMan转录试剂盒是最常用的miRNA图谱平台，miR-200C被认为具有混合失调。我们测量了各种分析的miRNA的HR的总体汇集效应估计为1.516，95%的可信区间为1.303-1.765，具有显著的p值。零假设检验的Z值为5.377，相应地注意到P值小于0.0001。这一结果表明，上调表达组的死亡风险被确定为高于下调表达组。在所研究的34个miRNAs中，有7个miRNAs与预后改善有关，特别是与这7个miRNAs(miR15b-5p、miR-548b、miR-519d、miR-1278、miR-145、miR-200C、HSA-miR139-3p)的过度表达有关。讨论：研究结果表明，在HNC中miRNAs的表达与化疗耐药之间更有可能存在复杂的关系，并可能成为潜在的治疗靶点。这篇综述提示，特定的miRNAs参与了HNC化疗耐药和敏感性的预测因素。对目前研究结果的检查表明，miRNA表达作为医学肿瘤学中的一个诊断生物标记物具有重要意义。
Background: Chemoresistance is a significant barrier to combating head and neck cancer, and decoding this resistance can widen the therapeutic application of such chemotherapeutic drugs. This systematic review and meta-analysis explores the influence of microRNA (miRNA) expressions on chemoresistance in head and neck cancers (HNC). The objective is to evaluate the theragnostic effects of microRNA expressions on chemoresistance in HNC patients and investigate the utility of miRNAs as biomarkers and avenues for new therapeutic targets. Methods: We performed a comprehensive bibliographic search that included the SCOPUS, PubMed, and Science Direct bibliographic databases. These searches conformed to a predefined set of search strategies. Following the PRISMA guidelines, inclusion and exclusion criteria were framed upon completing the literature search. The data items extracted were tabulated and collated in MS Excel. This spreadsheet was used to determine the effect size estimation for the theragnostic effects of miRNA expressions on chemoresistance in HNC, the hazard ratio (HR), and 95% confidence intervals (95% CI). The comprehensive meta-analysis was performed using the random effects model. Heterogeneity among the data collected was assessed using the Q test, Tau2, I2, and Z measures. Publication bias of the included studies was checked using the Egger’s bias indicator test, Orwin and classic fail-safe N test, Begg and Mazumdar rank collection test, and Duval and Tweedie’s trim and fill methods. Results: After collating the data from 23 studies, dysregulation of 34 miRNAs was observed in 2189 people. These data were gathered from 23 studies. Out of the 34 miRNAs considered, 22 were up-regulated, while 12 were down-regulated. The TaqMan transcription kits were the most used miRNA profiling platform, and miR-200c was seen to have a mixed dysregulation. We measured the overall pooled effect estimate of HR to be 1.516 for the various analyzed miRNA at a 95% confidence interval of 1.303–1.765, with a significant p-value. The null hypothesis test’s Z value was 5.377, and the p-value was correspondingly noted to be less than 0.0001. This outcome indicates that the risk of death is determined to be higher in up-regulated groups than in down-regulated groups. Among the 34 miRNAs that were investigated, seven miRNAs were associated with an improved prognosis, especially with the overexpression of these seven miRNAs (miR15b-5p, miR-548b, miR-519d, miR-1278, miR-145, miR-200c, Hsa- miR139-3p). Discussion: The findings reveal that intricate relationships between miRNAs’ expression and chemotherapeutic resistance in HNC are more likely to exist and can be potential therapeutic targets. This review suggests the involvement of specific miRNAs as predictors of chemoresistance and sensitivity in HNC. The examination of the current study results illustrates the significance of miRNA expression as a theragnostic biomarker in medical oncology.
登录
查看更多内容
影响因子：
--
作者：
Jayaraj R;Kumarasamy C;Madhav MR;Pandey V;Sabarimurugan S;Ramesh N;Gothandam KM;Baxi S
通讯作者：
Baxi S
影响因子：
8.4
作者：
Hess, Anne-Katrin;Mueer, Annika;Tinhofer, Ingeborg
通讯作者：
Tinhofer, Ingeborg
影响因子：
3.7
作者：
Duval, S;Tweedie, R
通讯作者：
Tweedie, R
影响因子：
6.4
作者：
Bray, Freddie;Ren, Jian-Song;Ferlay, Jacques
通讯作者：
Ferlay, Jacques
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG